Healthcare / Drug Manufacturers - Specialty & GenericBSE
$82.53
+0.76 (+0.93%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $8.1M · quality 42.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
36/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.1B
P/E
187.6x
↑EV/EBITDA
24.7x
↑ROE
1.0%
↑Gross Margin
22.1%
↓Debt/Equity
0.56
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-8.4%
FCF CAGR
—
FCF margin
3.1%
FCF / Net income
4.13x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $452.4M · net income $3.4M · FCF $13.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $452.4M | $452.4M | $449.2M | $520.8M | $589.6M |
| Net Income | $3.4M | $3.4M | $4.7M | $9.9M | $15.9M |
| EBITDA | $41.1M | $41.1M | $40.5M | $46.0M | $56.9M |
| EPS | 0.34 | 0.34 | 0.47 | 1.06 | 1.82 |
| Gross Margin | 22.1% | 22.1% | 26.0% | 21.3% | 28.5% |
| Operating Margin | 6.1% | 6.1% | 5.6% | 5.8% | 15.5% |
| Net Margin | 0.7% | 0.7% | 1.1% | 1.9% | 2.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.56 | 0.56 | 0.52 | 0.54 | 0.58 |
| Current Ratio | 2.53 | 2.53 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $13.9M | $13.9M | $-2.3M | $8.1M | $-16.8M |
| Returns | |||||
| ROE | 1.0% | 1.0% | 1.4% | 3.1% | 5.6% |
| Valuation | |||||
| P/E | 187.57 | 187.57 | — | — | — |
| EV/EBITDA | 24.71 | 24.71 | — | — | — |
| P/B | 2.42 | 2.42 | — | — | — |
| Growth & Yield | |||||
| Revenue Growth | 0.7% | 0.7% | -13.7% | -11.7% | — |
| EPS Growth | -27.7% | -27.7% | -55.7% | -41.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
178.2%
EPS terminal req.
$7.32
Spread vs growth
-205.9%
5Y implied EPS CAGR
92.0%
EPS terminal req.
$8.86
Spread vs growth
-119.6%
10Y implied EPS CAGR
45.3%
EPS terminal req.
$14.27
Spread vs growth
-73.0%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+157.7%
Start / end P/E
68.0x → 242.3x
EPS bridge
0.47 → 0.34
Residual
-70.9%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.